Internet Archive Scholar

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

Paula Dávila-Seijo, Esteban Dauden, M.A. Descalzo, Gregorio Carretero, José-Manuel Carrascosa, Francisco Vanaclocha, Francisco-José Gómez-García, Pablo De la Cueva-Dobao, Enrique Herrera-Ceballos, Isabel Belinchón, José-Luis López-Estebaranz, Merce Alsina (+15 others)
2017 Journal of Investigative Dermatology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (212.4 kB)
https://web.archive.org/web/20220312203803/https://www.jidonline.org/article/S0022-202X(16)32459-9/pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Information regarding the safety of biological drugs prescribed to psoriasis patients on daily and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases) to generate crude rates of infection during therapy with systemic drugs, including biological drugs (infliximab, etanercept, adalimumab, and ustekinumab) and nonbiological drugs (acitretin, cyclosporine, and methotrexate). We also
more » ... ted unadjusted and adjusted risk ratios (RRs) (with propensity score adjustment) of infection, serious infections, and recurrent infections of systemic therapies compared with methotrexate, using Poisson regression. Our study included records of 2,153 patients (7,867.5 person-years). The adjusted RR of overall infection was significantly increased in the groups treated with adalimumab with methotrexate (adjusted RR ¼ 2.13, 95% confidence interval [CI] ¼ 1.2e3.7), infliximab (adjusted RR ¼ 1.71, 95% CI ¼ 1.1e2.65), cyclosporine (adjusted RR ¼ 1.58, 95% CI ¼ 1.17e2.15), ustekinumab with methotrexate (adjusted RR ¼ 1.56, 95% CI ¼ 1.08e2.25), and etanercept (adjusted RR ¼ 1.34, 95% CI: 1.02e1.76) compared with methotrexate alone. Cyclosporine had a significant risk of serious infection (adjusted RR ¼ 3.12, 95% CI ¼ 1.1e8.8), followed by adalimumab combined with methotrexate (adjusted RR ¼ 3.28, 95% CI ¼ 0.8e13.5). Adalimumab in combination with methotrexate had the highest risk of infection recurrence (adjusted RR ¼ 4.33, 95% CI ¼ 2.27e8.24).
doi:10.1016/j.jid.2016.08.034 pmid:27677836 fatcat:z24mp4zddngehfpc4l3vkygh4u
Citation

Paula Dávila-Seijo, Esteban Dauden, M.A. Descalzo, Gregorio Carretero, José-Manuel Carrascosa, Francisco Vanaclocha, Francisco-José Gómez-García, Pablo De la Cueva-Dobao, Enrique Herrera-Ceballos, Isabel Belinchón, José-Luis López-Estebaranz, Merce Alsina, José-Luis Sánchez-Carazo, Marta Ferrán, Rosa Torrado, Carlos Ferrandiz, Raquel Rivera, Mar Llamas, Rafael Jiménez-Puya, Ignacio García-Doval, Beatriz Pérez Zafrilla, Carlos Muñoz-Santos, Victoria Mendiola-Fernández, Cristina Sánchez Roldán, Diana Ruiz-Genao, Begoña Echeverría, Sagrario Galiano Mejías. "Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry." Journal of Investigative Dermatology 137.2 (2017) 313-321